Insider Stock Buying Reaches US$751.8k On Vivani Medical

Yahoo FinanceJun 1 08:43 ET

Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant

Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic weight management in obese or overweight human patients with one or more risk factors, today announced the publication of positive proof-of-concept weight loss data with OKV-119, a miniature, subdermal, exenatide drug implant designed to treat feline obesity and diabetes, in the peer-reviewed BMC Veterinary Research.

BusinesswireMay 28 08:00 ET

Express News | EXCLUSIVE: Vivani Medical Tells Benzinga 'Felines Share Many Pathophysiologic Obesity Phenotypes With Humans, Further Supporting Clinical Evaluations of Miniature, Subdermal GLP-1 Implants for Obesity Reduction'

BenzingaMay 28 07:30 ET

Express News | EXCLUSIVE: Vivani Medical Tells Benzinga 'Data Published in BMC Veterinary Research Shows That OKV-119 Exenatide Implant Reduced Feline Weight'

BenzingaMay 28 07:30 ET

Express News | EXCLUSIVE: Vivani Medical Tells Benzinga Co Announces Publication Of Weight Loss Data Supporting Potential Veterinary Use Of OKV-119 Miniature, Long-Term GLP-1 Implant

BenzingaMay 28 07:30 ET

Buy Rating Justified: Vivani Medical's Promising NPM-115 Implant and Strategic Market Positioning

TipRanksMay 15 12:35 ET